03 February 2021
Hopes surrounding the U.S. stimulus package and better than expected quarterly results from Alphabet and Amazon are giving European markets a boost on Wednesday. Wall Street is expected to be in the green.
The major European stock markets are expected to move higher on Wednesday lunchtime on the back of Wall Street, supported by hope surrounding the US stimulus package and better than expected quarterly results from Alphabet and Amazon.
Wall Street is also expected to be in the green, according to U.S. index futures around 12:20 pm.
In Brussels, the Bel 20
was up 0.98% at around 12:20 pm, with the index of continuously quoted securities limiting its gains (+0.55%).
Argenx stands out and offers itself the luxury of jumping 8.5%, reaching a new record after having just completed a capital increase of 1 billion dollars. Aedifica takes 2% and Solvay 1.6%.
For its part, Umicore, which is to launch a takeover bid for one of its subsidiaries, is abandoning 0.4%. With a decline of 1%, KBC is in the red lantern. Colruyt abandons 0.8% while a broker has taken the value off its sales list.
Excluding Bel 20, Balta is up 18% in the wake of its results. KBC Securities has raised its advice on the value. Bone Therapeutics (+7%) and MDxHealth (+6.7%) are also worthy of note.
Melexis, which also published its results, dropped 3.5%. However, they were higher than expected. Fluxys fell by 2.5% and Kinepolis by 2.2%.
Le briefing actions belges
>The WDP quotation
was suspended this Wednesday at 2:20 p.m. until publication of the result of a private placement.
>Asit Biotech: today is the day creditors can decide on a plan for the judicial reorganization of the company. The listing is suspended.
>Belgian biotech argenx
raises a billion dollars. Argenx took advantage of its strong share price performance to solicit the market on both sides of the Atlantic. Successfully. Our article.
announced to its listed subsidiary Agosi that it intends to purchase the 8.8% of shares it does not already own from the minority shareholders of Agosi via a merger with a squeeze-out offer under German law. The press release.
: Exane BNP Paribas has raised its recommendation to « neutral » versus « underperform » (sell) before. The target price is now 50 euros, up from 46 euros.
: Morgan Stanley has lowered its recommendation to « neutral » versus « overweight » (buy) before. However, the target price is now 38 euros instead of 37 euros.
>The CEO of Melexis
is bowing out. While Melexis once again published figures that exceeded expectations, its CEO, Françoise Chombar, will pass on the torch and chair the board of directors. Our article.
revenues were down 8% to 151 million euros in the 4th quarter. Adjusted EBITDA rose by 41% to €28 million. 28 million. Margin rose from 12% to 18%. The press release.
>Balta: KBC Securities has raised its recommendation to « accumulate » versus « hold » before. The target share price has been raised from 1.4 to 2.5 euros.
acquires two eco-Suezmax vessels still under construction for a total amount of EUR 113 million. They will be delivered in January 2022. The press release.
>BlackRock Investment Management has reduced its seller’s position on Ontex
from 3.50% of the capital to 3.46% as of February 1.
>Cadian Capital Management reduced its short position in Agfa-Gevaert
from 1.78% of the capital to 1.66% as of February 1.
>The listing of Asit Biotech
has been suspended pending the issuance of a news release.
published a press release containing transparency declarations relating to its shareholding structure. The press release.
publishes its sustainability plan « Chain Reaction 2030 », outlining the company’s vision of achieving a fossil-free chemical industry by 2050. The press release.
>To be watched this Wednesday. Euro zone. PMI Services indicator January 10h. Inflation January 11h. US. Private sector employment January 14h15. ISM services indicator January 16h. Results: Biogen, AbbVie and PayPal.